Either genetic depletion of LSD1 or pharmacological inhibition has been shown to suppress the tumor growth, and therefore LSD1 is becoming a promising therapeutic target for cancer treatment (Schmitt et al., 2013). The gene discussed is KDM1A; the disease is neoplasm.